Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451175 | 0.86 | HPGD (0.56) | KDM4EMAPTSMN1; SMN2MEN1POLB | |
| SCHEMBL3451107 | 0.85 | ADORA1 (0.54) | ADORA1ADORA2AADORA3KDM4EMAPT | |
| SCHEMBL3450640 | 0.85 | PIK3CA (0.51) | ADORA1ADORA2AADORA3KDM4EMAPT | |
| SCHEMBL3451693 | 0.84 | ADORA1 (0.58) | ADORA1ADORA2AADORA3KDM4EMAPT | |
| SCHEMBL3451637 | 0.77 | HPGD (0.50) | KDM4EMAPTSMN1; SMN2MEN1POLB | |
| SCHEMBL3453289 | 0.76 | PTGS2 (0.48) | ADORA1ADORA2AADORA3MAPTSMN1; SMN2 | |
| SCHEMBL3451696 | 0.76 | IRAK1 (0.53) | ADORA1ADORA2AADORA3KDM4EMAPT | |
| SCHEMBL3728043 | 0.73 | ADORA1 (0.44) | ADORA1ADORA2AADORA3KDM4EMAPT | |
| SCHEMBL5181372 | 0.72 | ALOX5 (0.47) | KDM4EMAPTSMN1; SMN2MEN1POLB | |
| SCHEMBL3452078 | 0.71 | HPGD (0.47) | KDM4EMAPTSMN1; SMN2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | ADORA1 2067/4885ADORA2A 1490/4885ADORA3 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.